Dr. Stephen S. Flitman, M.D.
Neurology (Neurology Physician)
2601 N 3rd St, Ste 125
Phoenix, AZ 85004
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Albany Medical College of Union University (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 347
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: Albany Medical College of Union University
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
AZ license 20626
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Banner - University Medical Center Phoenix Phoenix, AZ
- St Josephs Hospital and Medical Center Phoenix, AZ
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 347
- Services billed
- 2,783
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 571 | 299 |
| Established patient office or other outpatient visit, 40-54 minutes | 176 | 128 |
| New patient office or other outpatient visit, 60-74 minutes | 49 | 49 |
| Established patient office or other outpatient visit, 20-29 minutes | 47 | 42 |
| New patient office or other outpatient visit, 45-59 minutes | 23 | 23 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 17 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 39 companies reported 235 payments worth $6,055 in total to this clinician.
| UCB, Inc. | $472 |
|---|---|
| Eisai Inc. | $470 |
| Pfizer Inc. | $462 |
| Alexion Pharmaceuticals, Inc. | $462 |
| Axsome Therapeutics, Inc. | $450 |
| AbbVie Inc. | $401 |
| Biogen, Inc. | $357 |
| Sk Life Science, Inc. | $233 |
| Food and Beverage | $5,805 |
|---|---|
| Consulting Fee | $150 |
| Education | $99.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Biogen, Inc. May 29, 2025 | Consulting Fee TYSABRI · Neurology | $150 |
| Harmony Biosciences LLC Jul 31, 2025 | Education in-kind | $99.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 6 companies. The companies reported $402,555 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (Targe…
E.r. Squibb & Sons, L.l.c. - A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants wit…
Janssen Research & Development, LLC - A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After …
Novartis Pharmaceuticals Corporation - A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
UCB SA · Completed · NCT04658186 - Ocrelizumab RMS High Dose Study
Genentech, Inc. - A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
UCB SA · Recruiting · NCT05077904 - Evaluation of Fenebrutinib in RMS patients II
Genentech, Inc. - An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease
UCB SA · Terminated · NCT05543252 - A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
UCB SA · Completed · NCT06055985 - Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.